Security
Adlai Nortye Group Ltd. American Depositary Shares · ANL
ANLNASDAQotherCurrentCIK 1944552Updated Oct 1, 2026
Name history
Adlai Nortye Ltd. · through Aug 19, 2026
ANL price & chart
Loading TradingView…
NASDAQ:ANL on TradingView ↗About the company
Adlai Nortye is a global clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies. The global infrastructure supports the efficient execution of our robust pipeline of drug candidates covering two key therapeutic areas: 1) Precision RAS pathway targeted therapies: including the oral pan-RAS(ON) inhibitor AN9025, and the CEACAM5-targeting ADC AN4035 engineered from the Company’s proprietary RASiCA™ (RAS Inhibitor Conjugated Antibody) platform, which efficiently delivers a potent pan-RAS(ON) inhibitor to the tumor site.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Profit or LossUSD | -51,869,000Source | -104,871,000Source | -58,790,000Source |
| Additional Financial Items | |||
| AdjustmentsForFinanceCostsUSD | 1,944,000Source | 791,000Source | 433,000Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | -4,202,000Source | 1,252,000Source | 10,117,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 2,450,000Source | 4,330,000Source | 6,082,000Source |
| GeneralAndAdministrativeExpenseUSD | 9,953,000Source | — | — |
| InterestPaidClassifiedAsFinancingActivitiesUSD | 1,871,000Source | 602,000Source | 292,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 1,020,000Source | 1,103,000Source | 1,070,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | 44,702,000Source | 50,234,000Source | 7,897,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesUSD | 33,000Source | 1,000Source | 17,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | — | 19,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | 48,542,000Source | 24,069,000Source | 13,315,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Additional Financial Items | |||
| AdministrativeExpenseUSD | 9,953,000Source | 15,289,000Source | 13,039,000Source |
| ApplicableTaxRatenumber | 0.25Source | 0.25Source | 0.25Source |
| BasicEarningsLossPerShareUSD per share | -0.54Source | -2.42Source | -2.31Source |
| CurrentTaxExpenseIncomeUSD | — | 643,000Source | — |
| DepreciationAndAmortisationExpenseUSD | 510,000Source | — | — |
| DepreciationRightofuseAssetsUSD | 866,000Source | 984,000Source | 1,090,000Source |
| DilutedEarningsLossPerShareUSD per share | -0.54Source | -2.42Source | -2.31Source |
| EmployeeBenefitsExpenseUSD | 5,994,000Source | — | — |
| FinanceCostsUSD | 1,944,000Source | 791,000Source | 433,000Source |
| GeneralAndAdministrativeExpenseUSD | 9,953,000Source | — | — |
| IncomeTaxExpenseContinuingOperationsUSD | — | 643,000Source | — |
| InterestExpenseOnLeaseLiabilitiesUSD | 50,000Source | 83,000Source | 133,000Source |
| OtherEmployeeExpenseUSD | 437,000Source | — | — |
| OtherOperatingIncomeExpenseUSD | 1,940,000Source | 890,000Source | 259,000Source |
| ProfessionalFeesExpenseUSD | 1,735,000Source | — | — |
| ProfitLossAttributableToOwnersOfParentUSD | -51,869,000Source | -104,871,000Source | -58,790,000Source |
| ProfitLossBeforeTaxUSD | -51,869,000Source | -104,228,000Source | -58,790,000Source |
| ProfitLossFromOperatingActivitiesUSD | -52,928,000Source | -67,551,000Source | -67,270,000Source |
| ResearchAndDevelopmentExpenseUSD | 44,915,000Source | 58,152,000Source | 54,490,000Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodUSD | -4,000Source | — | — |
Filing attachments
ea030697801ex99-1.htm · 6-K · 2026-09-30
Exhibit 99.1 Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) - Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. Dr. Liu brings nearly a decade of…
Read attachment ↗